CHUNCHEON, South Korea , Dec. 21, 2020 / PRNewswire / - The broad-spectrum antiviral therapeutic, 'hzVSF-v13 (humanized Virus Suppressing Factor)' developed by ImmuneMed, is in progress as a treatment for patients with pneumonia due to COVID-19. It is currently progressing smoothly with approval for phase 2 clinical trials in four countries, with results expected to be seen sequentially as early as Q3 2021.
The pediatric brain cancer known as diffuse intrinsic pontine glioma (DIPG) is almost uniformly fatal. In part, this is due to where and how it grows, forming as a diffuse net of cells in a part of the brainstem called the pons, which controls essential functions like breathing and swallowing. Another factor that makes DIPG especially dangerous is a lack of treatments - currently, there are no targeted therapies or immunotherapies proven effective to treat the condition, and the many chemotherapy clinical trials seeking to treat DIPG have been uniformly unsuccessful.
ImmuneMed, a South Korean biotech firm, will soon launch clinical trials of its investigational coronavirus treatment outside Korea, the company chief executive Kim Yoon-won told Maeil Business Newspaper on Wednesday.